Bioworld Technology CO., Ltd.



Cyclin D3 (G277) Peptide

Cat No.: BS1393P

Background

The inactive ternary complex of cyclin D/CDK4 and p27 Kip1 requires extracellular mitogenic stimuli for the release and degradation of p27 concomitant with a rise in cyclin D levels to affect progression through the restriction point and Rb-dependent entry into S-phase. The active complex of cyclin D/CDK4 targets the retinoblastoma protein for phosphorylation, allowing the release of E2F transcription factors that activate G1/S-phase gene expression. Levels of cyclin D protein drop upon withdrawal of growth factors through downregulation of protein expression and phosphorylation-dependent degradation. Although the D-type cyclins are not fully redundant, cyclin D3, like D1, plays a prominent role in differentiation and proliferation, which correlates with higher expression levels of cyclin D3 in various cancers.

Swiss-Prot

P30281

Applications

Blocking

Specificity

This peptide can be used with studies using BS1393 Cyclin D3 (G277) pAb.

Purification & Purity

Synthetic peptide Cyclin D3 (G277). (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at $4 \,^{\circ}{\rm C}$ short term. Aliquot and store at $-20 \,^{\circ}{\rm C}$ long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.